▲ Peaking
Business
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte shares surge following positive late-stage clinical trial results for its pneumococcal vaccine candidate.
Vaxcyte
1 trends tracked about this subject — the full history, oldest to newest below.